Epitan receives marketing approval for Zindaclin
By Ruth Beran
Tuesday, 08 November, 2005
Tuesday, 08 November, 2005
Epitan (ASX:EPT, ADR:EPTNY, XETRA:UR9) has received approval from the Therapeutic Goods Administration (TGA) for the registration of anti-acne treatment Zindaclin.
Zindaclin is a once-a-day clindamycin-based gel which Epitan's wholly-owned subsidiary Epipharm in-licensed from UK-based Pro-Strakan Pharmaceuticals (formerly Strakan) in July 2004. The product was submitted for registration from the TGA soon after.
Related News
Link between oestrogen and heart health found in women
Scientists found that oestrogen helps increase the ANXA1 protein, and when ANXA1 is missing, the...
Frequent nightmares accelerate aging, increase risk of death
Nghtmares independently predict faster biological aging and earlier mortality — even after...
Cardiac organoids bring hope for treating heart disease
Australian scientists have developed lab-grown, three-dimensional heart tissues known as cardiac...
